บทบาทของรังสีรักษา และเคมีบำบัดในมะเร็งรูทวาร

Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354-6.

Nigro ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826-9.

Leichman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 1985;78:211-5.

Northover J, Glynne-Jones R, Sebag-Montefi ore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the fi rst randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010;102:1123-8.

Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-9.

Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fl uorouracil and radiotherapy, and of salvage chemoradiation in the defi nitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup
study. J Clin Oncol 1996;14:2527-39.

Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fl uorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-21.

James R, Wan S, Glynne-Jones R, et al. A randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus. J Clin Oncol (Proc ASCO) 2009;27:[abstract LBA-4009].

Glynne-Jones R, Mawdsley S. Anal cancer: the end of the road for neoadjuvant chemoradiotherapy? J Clin Oncol 2008;26:3669-71.

Conroy T, Ducreux M, Lemanski C. Treatment intensifi cation by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): defi nitive analysis of the intergroup ACCORD-03 trial.
J Clin Oncol 2009;27:[abstract 4033].

Matzinger O, Roelofsen F, Mineur L, et al. Mitomycin C with continuous fl uorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Eur J Cancer 2009;45:2782-91.

Bosset JF, Roelofsen F, Morgan DA, et al. Shortened irradiation scheme, continuous infusion of 5-fl uorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003;39:45-51.

Glynne-Jones R, Meadows H, Wan S, et al. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008;72:119-26.

Eng C, Chang GJ, Das P, et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol 2009;27:[abstract 4116].

Olivatto LO, Meton F, Bezerra M, et al. Phase I study of cetuximab (CET) in combination with 5-fl urouracil (5FU), cisplatin (CP) and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC). J Clin Oncol 2008;26:[abstract 4609].

Konski A, Garcia M Jr, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72:114-8.

Glynne-Jones R, Sebag-Montefi ore D, Adams R, et al. "Mind the Gap"-The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I). Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]

Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010;28:5061-6.

Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 2010;116:4007-13.

Grigsby PW, Roberts HL, Perez CA. Femoral neck fracture following groin irradiation. Int J Radiat Oncol Biol Phys 1995;32:63-7.

Gilroy JS, Amdur RJ, Louis DA, et al. Irradiating the groin nodes without breaking a leg: a comparison of techniques for groin node irradiation. Med Dosim 2004;29:258-64.

Dittmer PH, Randall ME. A technique for inguinal node boost using photon fi elds defi ned by asymmetric collimator jaws. Radiother Oncol 2001;59:61-4.

Moran M, Lund MW, Ahmad M, et al. Improved treatment of pelvis and inguinal nodes using modifi ed segmental boost technique: dosimetric evaluation. Int J Radiat Oncol Biol Phys 2004;59:1523-30.

Menkarios C, Azria D, Laliberté B, et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007;2:41.